Bioxyne Limited (AU:BXN)
ASX:BXN
Want to see AU:BXN full AI Analyst Report?
Top Page
Bioxyne Limited
(Sydney:BXN)
Select Model
Select Model
Rating:82Outperform
Price Target:
AU$0.08
▲(97.50% Upside)
Action:Reiterated
Date:05/13/26
The score is led by strong financial performance (rapid revenue growth, solid margins, low leverage, and sharply improved free cash flow), supported by very low valuation (P/E 3.182). Technicals remain trend-positive but are tempered by overextended momentum signals (RSI/Stoch in the high 70s), which raises near-term volatility risk.
Positive Factors
Revenue Growth
Sustained high revenue growth demonstrates expanding market traction and product adoption in medical cannabis channels. Over 2-6 months this supports higher scale economics, strengthens negotiating leverage with distributors, and provides a larger base for reinvestment in R&D and commercialization.
Negative Factors
Regulatory & Market Access Dependence
Business outcomes are structurally tied to regulatory approvals and product registrations. Approval delays, changing prescribing rules or market access hurdles can materially slow revenue realization, extend commercialization timelines and increase compliance costs over months to quarters.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth
Sustained high revenue growth demonstrates expanding market traction and product adoption in medical cannabis channels. Over 2-6 months this supports higher scale economics, strengthens negotiating leverage with distributors, and provides a larger base for reinvestment in R&D and commercialization.
Read all positive factors
Bioxyne Limited (BXN) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$168.83M
Dividend YieldN/A
Average Volume (3M)4.35M
Price to Earnings (P/E)3.2
Beta (1Y)1.38
Revenue Growth174.51%
EPS Growth272.73%
CountryAU
Employees16
SectorConsumer Defensive
Sector Strength42
IndustryPackaged Foods
Share Statistics
EPS (TTM)<0.01
Shares Outstanding2,281,433,300
10 Day Avg. Volume2,483,521
30 Day Avg. Volume4,348,514
Financial Highlights & Ratios
PEG Ratio-0.13
Price to Book (P/B)7.54
Price to Sales (P/S)2.90
P/FCF Ratio22.82
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bioxyne Limited Business Overview & Revenue Model
Company Description
Bioxyne Limited, a life sciences and health products company, researches, develops, markets, and distributes dietary supplement and beauty products. It perates in two segments, Wholesale Sales and Direct Sales. The company engages in developing va...
How the Company Makes Money
Bioxyne Limited makes money primarily by generating revenue from the sale and distribution of medicinal cannabis products and related manufactured goods. Key revenue streams typically include: (1) product sales to pharmacies, clinics, wholesalers,...
Bioxyne Limited Financial Statement Overview
Summary
Income Statement
85
Very Positive
Balance Sheet
78
Positive
Cash Flow
82
Very Positive
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 49.17M | 30.42M | 9.33M | 5.16M | 463.64K | 2.11M |
| Gross Profit | 16.41M | 10.45M | 3.40M | 343.13K | -224.10K | 639.71K |
| EBITDA | 9.59M | 5.34M | -13.03M | -1.88M | -463.30K | -425.93K |
| Net Income | 8.97M | 4.90M | -13.33M | -1.94M | -494.02K | -495.73K |
Balance Sheet | ||||||
| Total Assets | 34.63M | 20.90M | 6.70M | 17.69M | 445.59K | 2.68M |
| Cash, Cash Equivalents and Short-Term Investments | 7.60M | 7.67M | 1.03M | 3.85M | 65.93K | 1.60M |
| Total Debt | 7.43M | 1.53M | 710.42K | 558.61K | 397.39K | 47.46K |
| Total Liabilities | 14.45M | 9.53M | 3.40M | 2.69M | 810.43K | 744.75K |
| Stockholders Equity | 20.17M | 11.68M | 3.61M | 15.14M | -364.84K | 1.88M |
Cash Flow | ||||||
| Free Cash Flow | -62.22K | 3.86M | -4.05M | -897.92K | -566.88K | 19.47K |
| Operating Cash Flow | 2.02M | 6.28M | -3.56M | -841.28K | -506.81K | 53.13K |
| Investing Cash Flow | -1.74M | -2.41M | -492.66K | 4.10M | 26.61K | -33.66K |
| Financing Cash Flow | 4.66M | 2.76M | 1.21M | 805.36K | 493.24K | -46.78K |
Bioxyne Limited Technical Analysis
Positive
0.04
Price Trends
0.06
Positive
0.05
Positive
0.05
Positive
Market Momentum
<0.01
Positive
50.12
Neutral
20.93
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:BXN, the sentiment is Positive. The current price of 0.04 is below the 20-day moving average (MA) of 0.07, below the 50-day MA of 0.06, and below the 200-day MA of 0.05, indicating a bullish trend. The MACD of <0.01 indicates Positive momentum. The RSI at 50.12 is Neutral, neither overbought nor oversold. The STOCH value of 20.93 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AU:BXN.
Bioxyne Limited Peers Comparison
UnderperformOutperform
Sector (62)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
82 Outperform | AU$168.83M | 3.18 | 56.29% | ― | 174.51% | 272.73% | |
78 Outperform | AU$148.63M | 7.66 | 12.22% | 2.19% | 27.60% | 96.31% | |
62 Neutral | $20.33B | 14.63 | -3.31% | 3.23% | 1.93% | -12.26% | |
46 Neutral | AU$34.05M | 22.20 | -53.68% | ― | -12.46% | 44.05% | |
44 Neutral | AU$26.12M | -12.65 | -321.20% | ― | 2.96% | -866.67% | |
41 Neutral | AU$8.46M | -1.62 | -44.35% | ― | -32.09% | 34.85% | |
39 Underperform | AU$4.60M | -0.92 | -92.72% | ― | 5.79% | 29.75% |
* Consumer Defensive Sector Average
AU:BXN
Bioxyne Limited
0.07
0.04
172.00%
AU:WNX
Wellnex Life Ltd
0.06
-0.28
-81.47%
AU:EVE
EVE Health Group Limited
0.03
>-0.01
-16.67%
AU:HCT
Holista Colltech Limited
0.07
0.02
33.96%
AU:CLV
Clover Corporation Limited
0.87
0.44
101.63%
AU:MBH
Maggie Beer Holdings Ltd.
0.07
0.02
45.10%
Bioxyne Limited Corporate Events
Bioxyne to Consolidate Shares, Options and Performance Rights
May 21, 2026
Bioxyne Limited has announced a consolidation of its securities, covering its ordinary fully paid shares, multiple series of options expiring in March 2027, and performance rights. The consolidation has a record date of 25 June 2026, with post-con...
Bioxyne calls June shareholder meeting as it leans into digital engagement and alternative therapeutics
May 21, 2026
Bioxyne Limited has called a General Meeting of shareholders for 19 June 2026 in Sydney, with materials available electronically in line with Australian regulatory provisions and a strong push for investors to lodge directed proxy votes online ahe...
Bioxyne calls June 2026 general meeting, urges proxy voting
May 21, 2026
Bioxyne Limited has called a General Meeting of shareholders to be held on 19 June 2026 at the offices of Addisons in Sydney, with the session commencing at 2:00 p.m. Sydney time. The company has circulated a Notice of Meeting and Explanatory Memo...
Bioxyne seeks ASX quotation for 1.27 million new ordinary shares
Apr 14, 2026
Bioxyne Limited has applied for quotation on the ASX of 1,267,797 ordinary fully paid shares, to be issued on 14 April 2026 under its BXN ticker. The new securities arise from the exercise or conversion of existing options or other convertible ins...
Bioxyne details Aurora Cannabis manufacturing deal and expected revenue uplift
Apr 1, 2026
Bioxyne Limited has provided supplementary details on its manufacturing agreement with Aurora Cannabis, confirming that the deal spans the full breadth of Bioxyne’s product range, including sublingual oils, vape products and pastille or gumm...
Bioxyne Strikes Global Manufacturing Pact with Aurora Cannabis
Apr 1, 2026
Bioxyne Limited, via its subsidiary Breathe Life Sciences, has signed a manufacturing agreement with Canadian-based Aurora Cannabis, a leading global medical cannabis company. The deal will see Breathe Life Sciences produce GMP-certified medicinal...
Bioxyne Leverages Unique Licensing to Target Growing Psychedelic Medicine Demand
Mar 24, 2026
Bioxyne Limited is promoting its role as a fast-growing pharmaceutical manufacturer specialising in cannabis, psilocybin and MDMA-based medicines aimed at patients with unmet clinical needs. The company highlights strong demand for psychedelic the...
Bioxyne to showcase expanding psychedelic and cannabis portfolio at virtual healthcare forum
Mar 24, 2026
Bioxyne Limited will present at the NWR Virtual Healthcare Conference, with Executive Director Jason Hine scheduled to deliver an investor-focused update via a virtual session, which will be accessible live and later as a recording. The appearance...
Bioxyne director Samuel Watson lifts stake via on-market share purchase
Mar 22, 2026
Bioxyne director Samuel Watson has increased his indirect shareholding in the company through an on-market purchase conducted via Breathe International Limited, a company in which he holds a controlling interest. The acquisition involved 1.8 milli...
Bioxyne issues 27.6m shares as executive commission under Listing Rule 7.1
Mar 20, 2026
Bioxyne Limited has issued 27,592,225 new shares at a deemed price of $0.025 per share to an executive as commission under an existing services agreement, using its placement capacity under ASX Listing Rule 7.1. The company stated it remains compl...
Bioxyne Issues Shares to Settle Commission Liability
Mar 20, 2026
Bioxyne Limited has applied for quotation on the ASX of 27,592,225 ordinary fully paid shares under the code BXN. The newly issued shares were created to settle an accrued commission liability arising from a service agreement after specified miles...
Bioxyne seeks ASX quotation for 1.83 million new shares
Mar 18, 2026
Bioxyne Limited has applied for quotation on the ASX of 1,825,000 ordinary fully paid shares, to be issued on 17 March 2026 under its existing ticker BXN. The new securities arise from the exercise or conversion of existing options or other conver...
Bioxyne Lifts FY26 Earnings Guidance After Strong First Half
Feb 26, 2026
Bioxyne has upgraded its FY26 adjusted EBITDA guidance to a range of $16.5 million to $19.0 million, up from $11.5 million to $13.5 million, after a stronger than expected first half. The company delivered H1 FY26 adjusted EBITDA of $8.3 million, ...
Bioxyne Profit Surges as Revenue Nearly Triples on Alternative Therapeutics Push
Feb 26, 2026
Bioxyne Limited reported a sharp improvement in its financial performance for the half year to 31 December 2025, with revenue from continuing operations rising 149% to $31.3 million and net profit attributable to members more than doubling to $7.3...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.